FTC's Pay-For-Delay Push May Hinder Pharma Patent Deals
The Federal Trade Commission's recent brief challenging a patent settlement over antidepressant Effexor shows the agency is intent on expanding the Third Circuit's K-Dur decision beyond traditional pay-for-delay settlements, a move...To view the full article, register now.
Already a subscriber? Click here to view full article